GV20 Therapeutics is leveraging artificial intelligence to develop better cancer therapeutics. Using their unique STEAD (Simultaneous Target Evaluation and Antibody Discovery) platform that integrates computation and experimentation to unlock the power of the human immune system, GV20 is discovering novel therapeutic targets and antibodies. Following discovery, targets are prioritized with functional genomics and big data. GV20’s lead candidate, GV20-0251, is a first-in-class antibody against a novel immune checkpoint, IGSF8, in clinical development as a therapy for solid tumors.

GV20 Therapeutics

GV20 Therapeutics Presents Promising Phase 1 Monotherapy Data on Novel Checkpoint Inhibitor GV20-0251 at ESMO Congress 2024 - PR Newswire

 GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune Checkpoint and Cancer Immunotherapy Target Apr 24, 2024Read More


              GV20
            

Proprietary platform discovers novel tumor-selective target-antibody pairs with speed and scale - Nature.com

Generation to Generation: Financial Aid Pushes the World Forward - Smith College Grécourt Gate

 GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-Class Antagonist ... 

 GV20 Therapeutics Presents Promising Phase 1 Monotherapy Data on Novel Checkpoint Inhibitor GV20-0251 at ESMO Congress 2024 Sept 16, 2024Read More


              GV20 Therapeutics to Present Clinical Data on GV20-0251 at the ESMO Congress 2024
            

GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-Class Antagonist Antibody Against the Novel Immune Checkpoint IGSF8, in Combination with KEYTRUDA® (pembrolizumab) - PR Newswire

GV20 Therapeutics Builds Experienced Leadership Team with Appointments of Three Key Executives - Business Wire

 GV20 Oncotherapy Completes Series B Financing 

 GV20 Therapeutics to Present at the Jefferies Healthcare Conference Private Biotech Day May 22, 2024Read More

Today, we announced our participation in the upcoming Jefferies Healthcare Conference Private Biotech Day.  More details here: https://bit.ly/3QU9MnH

GV20 Therapeutics Announces Appointment of Three Advisers - Business Wire

GV20 Therapeutics to Present Clinical Data on GV20-0251 at the ESMO Congress 2024 - PR Newswire

GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery - Yahoo Finance

Each year, The Posse Foundation identifies honorees who exhibit leadership, make significant contributions in the field of education, and positively affect people’s lives. We are thrilled to share that our Principal Scientist, Flavian D. Brown, was selected for the Posse Alumni category. He was recognized for his leadership, compassion, and ability to work in a team. He applies these qualities to his scientific world by mentoring younger scientists and leading teams worldwide.

Take a minute and watch this beautiful spotlight on who Flavian is and all the great work he’s doing for science. 

#oncology #biotech #AI #PosseHonoree

Science spotlight: Biotechs discover new checkpoint target, and more - BioCentury

 GV20 Therapeutics Presents Preclinical Data on GV20-0251 for Solid Tumors Targeting IGSF8 at AACR Annual ... 


              IGSF8 is an innate immune checkpoint and cancer immunotherapy target
            

https://lnkd.in/etkYZMzh


              GV20 Therapeutics Presents Promising Phase 1 Monotherapy Data on Novel Checkpoint Inhibitor GV20-0251 at ESMO Congress 2024
            

 GV20 Therapeutics Announces Publication in Cell Highlighting the Discovery of IGSF8 as an Innate Immune ... 

 GV20 Therapeutics to Present Clinical Data on GV20-0251 at the ESMO Congress 2024 Aug 21, 2024Read More

 GV20 Therapeutics Joins NVIDIA Inception to Develop AI Models for Drug and Target Discovery 


              Connect with Ying Gong, PhD at #BIO2024
            

 Compositions and methods for treating autoimmune diseases and cancers by … 

 GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251, a First-in-Class Antagonist Antibody Against the Novel Immune Checkpoint IGSF8, in Combination with KEYTRUDA® (pembrolizumab) Apr 18, 2024Read More

GV20 Therapeutics

Business:

Drug notes:

About: